Business ❯ Finance ❯ Corporate Finance

Pharmaceuticals

Novo Nordisk GSK Eli Lilly Pfizer Sales Performance Financial Performance AstraZeneca Merck & Co Inc Merck Dr Reddy's Laboratories Divi's Laboratories Clinical Trials Obesity Treatments Amylyx Pharmaceuticals Ajanta Pharma Glenmark Pharmaceuticals Aurobindo Pharma Drug Development Pfizer Inc. Merck & Co. Kiniksa Pharmaceuticals Dr. Reddy's Laboratories Organon Revenue Growth Biotechnology Cipla Ltd Regeneron Pharmaceuticals Vaccine Development Dermatology Earnings Calls Emcure Pharmaceuticals Novartis AbbVie GlaxoSmithKline Pharmaceuticals Earnings Reports Product Performance Sanofi BioSyent Inc. Drug Sales

AstraZeneca Tops Q1 Forecasts, Reaffirms 2026 Outlook as Oncology Fuels Growth

Strong pipeline progress signals momentum toward the company's 2030 $80 billion sales goal.

Regeneron Tops Q1 Estimates as Dupixent and Libtayo Outpace Eylea

ANI Pharmaceuticals Posts Record Quarter as Rare-Disease Drugs Power 29.6% Sales Jump

Collegium Reports Record 2025 Results, Projects Strong 2026 for Jornay as Hikma Generic Nears

Eli Lilly’s Q4 Beat and Bullish Outlook Give Way to Stock Drop on Low-Cost GLP-1 Pills

Pfizer Tops Q4 Estimates but Posts Loss on $4.4 Billion Charge, Reaffirms 2026 Outlook

Pfizer Sets 2026 Targets Below Wall Street as COVID Sales Fade, Patent Pressure Builds

Organon Beats Q3 Estimates as Segment Performance Splits and Guidance Signals Confuse

GSK Lifts 2025 Guidance After Strong Quarter, Says Tariff Risks Covered

Regeneron Tops Q3 Forecasts on Dupixent Strength as Eylea HD Faces FDA Delay

Dupixent Powers Sanofi’s Q3 as Vaccine Sales Slip

Eli Lilly Raises 2025 Outlook as Tirzepatide Sales Soar, Orforglipron Misses Marks